Medscape Inc. – Trademark Portfolio
Entity Type: 03
Medscape Inc. holds 17 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 11 filings in this category. The portfolio also extends into Class 9 (Computers & Electronics) across 4 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include MEDPULSE. The owner is based in Boulder, CO.
P.O. Box 802
Boulder, CO 803060302
Showing of trademarks Trademarks
Trademark Classifications
Medscape Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Education; providing of training; entertainment; sporting and cultural activities
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does Medscape Inc. have?
Medscape Inc. has 17 U.S. trademarks filed with the USPTO. Of these, 1 registered, 14 abandoned, 2 cancelled.
What trademark classes does Medscape Inc. file in?
Medscape Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 9 (Computers & Electronics), Class 41 (Education & Entertainment), Class 35 (Advertising & Business). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Medscape Inc.'s most well-known trademarks?
Medscape Inc.'s registered trademark portfolio includes well-known marks such as MEDPULSE. These are among 1 currently registered trademark in the portfolio.
What is Medscape Inc.'s trademark registration success rate?
Medscape Inc. has a 6% trademark registration rate, with 1 out of 17 resolved applications resulting in successful registration. Currently, 0 applications are pending review.